Researcher Profile

Researcher Profile

Hong Zheng, MD, PhD

Hong Zheng, MD, PhD

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Associate Professor, Department of Microbiology and Immunology
Scientific Program:Mechanisms of Carcinogenesis
Disease Teams:
Bone Marrow Transplantation
Immunotherapy
Leukemia and Lymphoma
hxz18@psu.edu

Research Interests

Dr. Hong Zheng's research focus is transplant immunology and developmental therapeutics for leukemia. Her study is dedicated to improve the understanding of the complex immune response involved in leukemia pathogenesis and allogeneic hematopoietic stem cell transplantation, and subsequently develop effective leukemia therapeutics.

Currently, she is involved in developing early-phase clinical studies testing the safety and efficacy of immunotherapy for leukemia. Her laboratory studies involve targeting T-cell inhibitory mechanisms as a strategy to improve anti-leukemia immunity.

  • T-Lymphocytes
  • Leukemia
  • Acute Myeloid Leukemia
  • Therapeutics
  • Heat-Shock Proteins
  • Neoplasms
  • Dendritic Cells
  • Non-Small Cell Lung Carcinoma
  • Graft vs Host Disease
  • Immunotherapy
  • Transplants
  • Cross-Priming

Clinical Trials

Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Collection of Blood for Investigation and Characterization of Circulating Tumor Cells (CTCs) in Cancer Patients with Microdevices
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Recent Publications

2019

Rice, SJ, Liu, X, Zhang, J, Jia, B, Zheng, H & Belani, C 2019, 'Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling', Lung Cancer, vol. 131, pp. 58-61. https://doi.org/10.1016/j.lungcan.2019.03.014
Kong, Y, Jia, B, Zhao, C, Claxton, D, Sharma, A, Annageldiyev, C, Fotos, J, Zeng, H, Paulson, R, Prabhu, KS & Zheng, H 2019, 'Downregulation of CD73 associates with T cell exhaustion in AML patients' Journal of Hematology and Oncology, vol. 12, no. 1, 40. https://doi.org/10.1186/s13045-019-0728-3
Jia, B, Zhao, C, Rakszawski, KL, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Wang, M, Shike, H, Bayerl, M, Sivik, JM, Schell, T, Drabick, J, Hohl, R & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Kong, Y, Tian, Y, Hao, Y, Chong, X, Xiao, J, Yang, D, Song, C, Han, J, Dai, G, Zhang, F, Zheng, H, Zhao, H & Zeng, H 2019, 'Two types of poor immunological responder showing distinct responses to long-term HAART', International Journal of Infectious Diseases, vol. 86, pp. 178-187. https://doi.org/10.1016/j.ijid.2019.07.037

2018

Song, Y, Wang, B, Song, R, Hao, Y, Wang, D, Li, Y, Jiang, Y, Xu, L, Ma, Y, Zheng, H, Kong, Y & Zeng, H 2018, ' T-cell Immunoglobulin and ITIM Domain Contributes to CD8 + T-cell Immunosenescence ', Aging cell, vol. 17, no. 2, e12716. https://doi.org/10.1111/acel.12716
Jia, B, Wang, L, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, T, Hohl, R & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34. https://doi.org/10.1038/s41408-018-0069-4
Zhu, L, Liu, L, Zhang, Y, Pu, L, Liu, J, Li, X, Chen, Z, Hao, Y, Wang, B, Han, J, Li, G, Liang, S, Xiong, H, Zheng, H, Li, A, Xu, J & Zeng, H 2018, 'High Level of Neutrophil Extracellular Traps Correlates with Poor Prognosis of Severe Influenza A Infection', Journal of Infectious Diseases, vol. 217, no. 3, pp. 428-437. https://doi.org/10.1093/infdis/jix475
Wang, L, Jia, B, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, R & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML', OncoImmunology, vol. 7, no. 9, e1469594. https://doi.org/10.1080/2162402X.2018.1469594

2017

Hou, P, Wu, C, Wang, Y, Qi, R, Bhavanasi, D, Zuo, Z, Dos Santos, C, Chen, S, Chen, Y, Zheng, H, Wang, H, Perl, A, Guo, D & Huang, J 2017, 'A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220', Cancer Research, vol. 77, no. 16, pp. 4402-4413. https://doi.org/10.1158/0008-5472.CAN-16-1627
Zhu, L, Kong, Y, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, T, Hohl, R, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124. https://doi.org/10.1186/s13045-017-0486-z
Jiang, P, Li, S, Lai, J, Zheng, H, Lin, C, Shi, P & Wang, Y 2017, 'Nanoparticle-Programmed Surface for Drug Release and Cell Regulation via Reversible Hybridization Reaction', ACS Applied Materials and Interfaces, vol. 9, no. 5, pp. 4467-4474. https://doi.org/10.1021/acsami.6b14355

2016

Zheng, H, Liu, X, Zhang, J, Rice, SJ, Wagman, M, Kong, Y, Zhu, L, Zhu, J, Joshi, M & Belani, C 2016, 'Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer', Oncotarget, vol. 7, no. 35, pp. 56233-56240. https://doi.org/10.18632/oncotarget.9316
Vasekar, M, Rizvi, S, Liu, X, Vrana, K & Zheng, H 2016, 'Novel immunotherapies for hematological malignancies', Current Molecular Pharmacology, vol. 9, no. 3, pp. 264-271. https://doi.org/10.2174/1874467208666150716121253
Kong, Y, Zhu, L, Schell, T, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, George, M, Zeng, H & Zheng, H 2016, 'T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients', Clinical Cancer Research, vol. 22, no. 12, pp. 3057-3066. https://doi.org/10.1158/1078-0432.CCR-15-2626
Rael, E, Rakszawski, KL, Koller, K, Bayerl, M, Butte, M & Zheng, H 2016, 'Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma', Biomarker Research, vol. 4, no. 1, 7. https://doi.org/10.1186/s40364-016-0061-8

2015

Kong, Y, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, Zhu, L, Zeng, H, Schell, T & Zheng, H 2015, ' PD-1 hi TIM-3 + T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation ', Blood Cancer Journal, vol. 5, no. 7, e330. https://doi.org/10.1038/bcj.2015.58

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)